Abstract 13610: Myeloid Cell-Specific Pyruvate Kinase M2 Deletion Accelerates Thrombus Resolution in the Mouse Inferior Vena Cava Stenosis Model
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.13610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Ivan Budnik und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Post-thrombotic syndrome (PTS) is the most common chronic complication of deep vein thrombosis. The pathophysiology of PTS is rooted in incomplete venous thrombus (VT) resolution, which creates persistent vein obstruction and sustains chronic inflammation in the venous wall. No therapy currently exists to actively promote VT resolution. Macrophages play a significant role in chronic inflammation, and the glycolytic enzyme pyruvate kinase M2 (PKM2) has emerged as a critical driver of a pro-inflammatory macrophage phenotype. Hypothesis: Myeloid cell-specific PKM2 deletion will promote a pro-resolving macrophage phenotype and accelerate VT resolution.
Methods
Male myeloid-specific PKM2-deficient (PKM2 fl/fl LysMCre + ) and control (PKM2 fl/fl ) mice (n=10/group), aged 3-4 months, were subjected to inferior vena cava (IVC) stenosis. VT volume was evaluated using serial magnetic resonance angiography on days 2, 7, 14, and 21 post-stenosis. The primary readout was time to half-maximal VT volume. qPCR was used to assess inflammatory gene expression, and fluorescence microscopy was used to evaluate efferocytosis of PKH26-labeled red blood cells (RBCs) by bone marrow-derived macrophages (BMDMs). Flow cytometry was used to assess efferocytosis of PKH26-labeled RBCs by macrophages isolated from VT and efferocytosis receptor expression in both BMDMs and VT macrophages.
Results
Compared with controls, PKM2-deficient mice had lower mean VT volumes on day 2 ( p < 0.05) and day 7 ( p < 0.001) post-stenosis and reached half-maximal VT volume earlier (6.8 vs. 9.0 days post-stenosis, p < 0.001). PKM2-deficient BMDMs showed reduced proinflammatory ( Ccl2 , Il1b , Il12b , and Nos2 , all p < 0.01) and increased anti-inflammatory ( Arg1 and Il10 , all p < 0.001) gene expression. PKM2-deficient BMDM cultures exhibited a significantly greater percentage of macrophages with engulfed RBCs ( p = 0.002), and PKM2-deficient macrophages isolated from VT showed increased PHK26 mean fluorescence intensity ( p = 0.005). Surface MERTK was higher in PKM2-deficient macrophages both in vitro ( p = 0.036) and in vivo ( p = 0.003); CD36 increased in vitro ( p = 0.002), whereas AXL was unchanged.
Conclusion
Myeloid cell-specific PKM2 deletion accelerates VT resolution and promotes a pro-resolving macrophage phenotype characterized by increased MERTK expression and efferocytosis activity. These findings identify macrophage PKM2 as a candidate therapeutic target to actively promote resolution of the VT.
Zitieren
APA
Budnik, I., Kumskova, M., Jha, A. B., & Chauhan, A. K. (2026). Abstract 13610: Myeloid Cell-Specific Pyruvate Kinase M2 Deletion Accelerates Thrombus Resolution in the Mouse Inferior Vena Cava Stenosis Model. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.13610
Vancouver
Budnik I, Kumskova M, Jha AB, Chauhan AK. Abstract 13610: Myeloid Cell-Specific Pyruvate Kinase M2 Deletion Accelerates Thrombus Resolution in the Mouse Inferior Vena Cava Stenosis Model. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.13610
BibTeX
@article{Budnik2026,
author = {Budnik, Ivan and Kumskova, Mariia and Jha, Abhishek B and Chauhan, Anil K},
title = {Abstract 13610: Myeloid Cell-Specific Pyruvate Kinase M2 Deletion Accelerates Thrombus Resolution in the Mouse Inferior Vena Cava Stenosis Model},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.13610}
}
EUVIMED